By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


SEARCH JOBS


Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.


Key Statistics


Email:
Ownership: Public

Web Site: Gilead
Employees: 4,000
Symbol: GILD
 



Industry
Biotechnology






Company News
Japan’s Ministry Of Health, Labour And Welfare Approves Gilead (GILD)’s Sovaldi (Sofosbuvir) For The Treatment Of Genotype 2 Chronic Hepatitis C 3/26/2015 9:20:03 AM
Gilead (GILD)'s $600 Million Man 3/25/2015 12:24:01 PM
Gilead (GILD) Release: Multiple Provinces Align To Provide Public Funding For Harvoni, The First Single Tablet Regimen For The Treatment Of Genotype 1 Chronic Hepatitis C Virus Infection 3/24/2015 2:22:56 PM
Gilead (GILD) Warns After Nine Hepatitis Patients Taking Heart Drug Develop Condition, One Dies From Cardiac Arrest 3/23/2015 6:03:21 AM
Hetero Received Generic Sofosbuvir (Gilead (GILD)'s Sovaldi) Approval From Drug Controller General Of India (DCGI) 3/12/2015 11:38:47 AM
Gilead (GILD) To Present At The Barclays Global Healthcare Conference On Wednesday, March 11 3/11/2015 10:20:05 AM
Gilead (GILD) To Present At The Cowen and Company 35th Annual Health Care Conference On Tuesday, March 3 3/3/2015 11:58:04 AM
Gilead (GILD) Announces Phase 3 Results For Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) 2/27/2015 10:40:52 AM
Gilead (GILD) Announces SVR12 Rates From Phase III Study Evaluating Harvoni For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 2/27/2015 6:18:07 AM
Gilead (GILD)'s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV 2/27/2015 6:16:45 AM
12345678910...
//-->